<DOC>
	<DOC>NCT01898078</DOC>
	<brief_summary>This is an open-label, multicenter, phase 1 study with the primary objective of evaluating the effect of food on the single-dose PK properties of alisertib administered as the ECT formulation. The secondary objective is to further evaluate the safety and tolerability of alisertib.</brief_summary>
	<brief_title>Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>18 years or older Histologically or cytologically confirmed advanced tumors or lymphomas for which standard curative or lifeprolonging treatment does not exist, or is no longer effective or tolerable Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Patient must meet protocolspecified laboratory values Female patients who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time or agree to practice true abstinence Male patients who agree to practice effective barrier contraception during the entire study and through 4 months after the last dose of study drug OR agree to practice true abstinence Prior or current investigational therapies within 4 weeks before the first dose of alisertib Female patients who are lactating or pregnant Patient requiring treatment with clinically significant enzyme inducers, such as the enzymeinducing antiepileptic drugs phenytoin, carbamazepine, or phenobarbital, or rifampin, rifabutin, rifapentine, or St. John's wort within 14 days before the first dose of alisertib and during the study Medical conditions requiring daily, chronic, or regular use of proton pump inhibitors(PPIs) within 7 days preceding the first dose of alisertib, or H2receptor antagonists Patient requiring systemic anticoagulation Ongoing nausea or vomiting that is Grade 2 or worse in intensity Known GI disease or GI procedures that could interfere with the oral absorption, excretion, or tolerance of alisertib History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe chronic obstructive pulmonary disease Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface antigenpositive status, or known or suspected active hepatitis C infection Patients who are lactoseintolerant or are unwilling/unable to consume the protocol specified standardized highfat breakfast Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MLN8237</keyword>
	<keyword>alisertib</keyword>
	<keyword>food effects</keyword>
</DOC>